Detection of *Trichomonas vaginalis* antigen in women by enzyme immunoassay

A YULE,* M C A GELLAN,† J D ORIEL,† J P ACKERS,*

*From the Department of *Medical Protozoology, London School of Hygiene and Tropical Medicine, and the Department of †Genitourinary Medicine, University College Hospital, London*

**SUMMARY** An enzyme immunoassay (EIA) was developed for the detection of *Trichomonas vaginalis* antigen in vaginal swabs. Four hundred and eighty two women attending a sexually transmitted disease (STD) clinic were tested; 44 (9·1%) were positive by culture, 32 (6·6%) were positive by wet film examination, and 54 (11·2%) were considered to be positive for trichomonal antigen by EIA. Taking culture as the reference method, the EIA had a sensitivity of 93·2% and a specificity of 97·5%. The predictive value of a positive test was 82% and that of a negative test was 99·3%.

Despite the widespread use of metronidazole and related chemotherapeutic agents, the incidence of *Trichomonas vaginalis* infection in England and Wales has remained constant over the past decade.¹ This has been partly due to the lack of an effective diagnostic test for this sexually transmitted protozoan parasite. Wet film microscopy misses 20–30% of those cases detected by culture methods;⁶ results of cultures are not available for at least 48 hours and the advantage of initiating treatment on the patient's first visit is lost. Serodiagnostic tests have not attained the specificity and sensitivity required for clinical use.³ We developed an enzyme immunoassay (EIA) for the detection of *T vaginalis* antigen and evaluated its performance with vaginal swabs taken from 482 women attending a sexually transmitted disease clinic. The assay is of the tandem type and uses the same affinity isolated polyclonal antibody fraction as both capture antibody and biotinylated indicator antibody.

**Patients and methods**

Four hundred and eighty two female outpatients attending the department of genito-urinary medicine (University College Hospital, London) were tested. Vaginal material for wet film microscopy, *T vaginalis* culture, and EIA was collected on cotton swabs. Culture swabs were inoculated into 10 ml modified Diamond's trypticase, yeast extract, maltose (TYM) medium⁴ supplemented with 10% horse serum, 1000 U/ml penicillin, 0·25 mg/ml streptomycin, and 0·025 mg/ml amphotericin B. Swabs taken for antigen detection by EIA were broken off into 1 ml phosphate buffered saline (PBS) containing 0·05% (v/v) Tween 20 and 0·05% (w/v) sodium azide (PBS–Tween 20) and stored at 4°C. Samples were assayed within 24 hours of collection or stored at −20°C for later testing. Culture tubes were examined microscopically for motile parasites after two and six days of incubation at 37°C.

**Preparation of trichomonal antigen**

*T vaginalis* isolates LUMP 1910 and LUMP 1042 used for rabbit immunisation were cultured in Meyer's HSP–1 medium⁵ supplemented with 15% rabbit serum, 1000 U/ml penicillin, and 0·25 mg/ml streptomycin. Isolates 1910 and 1911 (used for soluble antigen and Nonidet P40 lyase preparation) were cultured in Diamond's trypticase, yeast extract, maltose (TYM) medium. Organisms were washed three times with PBS before use or storage at −20°C. Pelleted trichomonads (5 × 10⁷ cells) were resuspended in 3 ml PBS, frozen at −20°C, and thawed at 4°C; the process was repeated to give three freeze-thaw cycles. After centrifugation (2000 × g for 15 minutes at 4°C) the soluble antigen fraction was assayed for protein content⁶ and stored at −20°C.

**Antitrichomonas antiserum**

Two New Zealand white rabbits were immunised intramuscularly with 2 × 10⁶ organisms (comprising
equal numbers of isolates 1910 and 1042) in Freund's Complete Adjuvant and boosted on days 14 and 28 with the same dose in Incomplete Adjuvant. Blood was collected on day 35.

**AFFINITY ISOLATION OF SPECIFIC ANTIBODY**

Trichomonal protein was extracted by lysis with the non-ionic detergent Nonidet P40 (NP40, BDH 56009). A 1 ml pellet of washed *T vaginalis* isolate 1911 (10⁶ cells) was resuspended in 5 ml lysis medium: 0·02M Tris-hydrochloric acid, 0·15M sodium chloride (pH 8·0), containing 0·5% NP40 (v/v), 0·001M phenylmethylsulphonyl fluoride (Sigma P7626), 0·001M iodoacetamide (Sigma 1–6125), and 10 mg/l Na-p-tosyl-L-lysine chloromethyl ketone (Sigma T–7254). After 15 minutes of incubation at 0°C the mixture was centrifuged at 2000 × g for 15 minutes at 4°C, the supernatant dialysed against 2 × 11 changes of 0·1M sodium carbonate, 0·15M sodium chloride (pH 8·3), and the protein content determined. A column of NP40 lysate protein coupled to cyanogen bromide activated Sepharose 4B (Pharmacia) was prepared according to the manufacturer's instructions using 6 mg protein/ml gel. A 5 ml aliquot of pooled immune rabbit serum was applied to an equal volume of coupled gel, the column washed extensively with PBS, and bound antibody eluted with 0·1M glycine-hydrochloric acid (pH 2·8). The pH of eluted fractions was immediately adjusted to 7·8 by collection into 1M Tris (0·2 ml/5 ml fraction). Fractions containing antibody were pooled and dialysed against 0·1M sodium hydroxide carbonate (pH 9·0) before concentration to 0·5–1 mg/ml by ultrafiltration to yield anti-*T vaginalis* immunoglobulin (ATV-Ig).

**BIOTINYLLATION OF ATV-IG**

N-hydroxysuccinamido-biotin (Sigma H-1759) was dissolved at 5 mg/ml in dimethyl sulphoxide (BDH 56009) and added to ATV-Ig in the ratio of 1:1 (by weight). After four hours of incubation at room temperature the mixture was dialysed against PBS before aliquots of 0·1 ml were taken and stored at −20°C.

**AVIDIN-ALKALINE PHOSPHATASE (AV-ALP) CONJUGATE**

Avidin (Sigma A-9275) was conjugated to alkaline phosphatase (Sigma P-6774) by a modified glutaraldehyde procedure.⁷ An avidin:enzyme ratio of 1:2 (by weight) was used.

**EIA PROCEDURE**

Microtitre plate (NUNC Immuno II) wells were coated with 0·1 ml ATV-Ig (5 μg/ml in 0·05M carbonate-bicarbonate buffer, pH 9·8) overnight at 4°C and stored at the same temperature; antibody coated plates had a minimum shelf life of two weeks. All subsequent incubations were at room temperature. Plates were washed four times with distilled water containing 0·05% Tween 20 (DW-Tween 20) just before use. Sample tubes were vortex mixed, the swab discarded, and 0·1 ml added to triplicate wells. After two hours of incubation in a moist box plates were washed five times with DW–Tween 20 and 0·1 ml biotinylated ATV-Ig (5 μg/ml in PBS–Tween 20 containing 1% rabbit serum) added to each well. Plates were incubated for one hour before being washed five times with DW–Tween 20. A 0·1 ml volume of Av-ALP (1/1500 in PBS–Tween 20 containing 0·5%, w/v, bovine serum albumin, Sigma A-7906) was added to each well and the plates reincubated for 30 minutes. After again washing five times with DW–Tween 20 colour was developed by the addition of 0·1 ml p-nitrophenol phosphate substrate solution to each well (Sigma 104–105, 1 mg/ml in 0·05M carbonate-bicarbonate buffer containing 0·002M magnesium chloride, pH 9·8). The reaction was terminated after 30 minutes by the addition of 0·05 ml 0·02M L-cysteine (Sigma C-7755) to each well. Optical density was measured at 405 nm using a Dynatech MR 600 microplate reader.

**Results**

Of the specimens from 482 women tested, 44 (9·1%) were positive for *T vaginalis* on culture; 32 (6·6%) of these were also positive on wet film examination. Culture results were used to select an appropriate cut off point for the EIA. Two controls were included on each plate: a negative control in which PBS–Tween 20 was substituted for the test sample, and a positive control consisting of soluble trichomonal antigen at 100 ng/ml in PBS–Tween 20. A sample was considered to be positive if the mean test optical density was greater than or equal to the mean optical density of the 100 ng/ml positive control after subtraction of the mean negative control optical density value from both. An additional 500 ng soluble antigen/ml control provided a readily visible marker of assay performance.

Using the above definition, 41 of 44 with positive results on culture were also considered to be positive by EIA (8·5% of the total number tested); a further nine samples were positive by EIA but negative on culture. Antigen was not detected by EIA in samples from three women who were negative on culture after two days of incubation but became positive on culture after six days. Taking culture as the reference method, the EIA had a sensitivity of 93·2% and a specificity of 97·5%. The predictive value of a positive test was 82%, and the predictive value of a negative test was 99·3%.
Discussion

This preliminary study indicates that the EIA is highly specific; 431 culture negative and EIA negative samples gave uniformly low background optical density values with no apparent interference by normal or pathological vaginal flora or in the presence of red blood cells, degraded epithelial cells, or large numbers of leucocytes. The clinical histories of nine women giving false positive EIA results showed that at the time of sampling five women had vaginal symptoms suggestive of *T vaginalis* infection, while four women were asymptomatic.

The optical density values obtained with false positive samples were comparable with those obtained with several samples positive on culture and indicated the presence of antigen at concentrations equivalent to 100–1000 ng soluble trichomonal antigen fraction/ml. This suggests the possibility of culture failure in at least some of these cases and illustrates the problem of selecting a suitable reference method when assessing diagnostic tests for infectious agents.

A second possible cause is the difference in the quantity of vaginal material obtained when separate swabs are taken for culture and antigen detection; the order of collection was not stipulated for the purpose of this study. This may have contributed to the failure of EIA to detect trichomonal antigen in three samples which were negative on culture after two days but positive after six days of incubation, suggesting the presence of only small numbers of organisms (and therefore low antigen titres) in these patients. One of these isolates was compared with a number of isolates from samples giving high optical density values in the EIA for its ability to inhibit the binding of a predetermined quantity of the polyclonal anti-*T vaginalis* serum to soluble trichomonal antigen; no noticeable differences were found, indicating that EIA failure was not due to antigenic heterogeneity between isolates.

Most of the samples positive on culture gave high optical density values (>1.0 units) and could be detected visually within minutes of the addition of substrate. This indicates that considerable quantities of antigen (equivalent to 5–10 µg soluble antigen fraction/ml) are present in the vagina during *T vaginalis* infection, and makes the prospect of a rapid immunodiagnostic test which would combine the sensitivity of culture with the speed and simplicity of wet film examination a realistic one. We are at present examining the feasibility of such a test using high affinity monoclonal antibodies in a two site simultaneous assay.

We thank the medical and nursing staff of the department of genitourinary medicine, University College Hospital, for their help. This study was supported by the Medical Research Council.

References

4 Diamond LS. The establishment of various trichomonads of animals and man in axenic culture. *J Parasitol* 1957;43:488–90.

Requests for reprints to: Dr JP Ackers, Department of Medical Protozoology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, England.
Detection of Trichomonas vaginalis antigen in women by enzyme immunoassay.
A Yule, M C Gellan, J D Oriel and J P Ackers

J Clin Pathol 1987 40: 566-568
doi: 10.1136/jcp.40.5.566

Updated information and services can be found at:
http://jcp.bmj.com/content/40/5/566

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/